Therapeutic modalities in hepatitis C: Challenges and development

Journal of Viral Hepatitis

Volumn 12, Issue 1, 2005, Pages 10-19

  Moreno Otero, R ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Chronic hepatitis C; Combination therapy; Hepatitis C virus; Pegylated interferon alpha; Ribavirin; Treatment

Indexed keywords

ACETYLCYSTEINE; ALPHA INTERFERON; AMANTADINE; MACROGOL; OFLOXACIN; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN; THYMOSIN ALPHA1; URSODEOXYCHOLIC ACID;

ADULT; ANTIGENICITY; ANTIVIRAL ACTIVITY; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION RISK; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REVIEW; T LYMPHOCYTE ACTIVATION; VIRUS REPLICATION;

DRUG THERAPY, COMBINATION; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERONS; LIVER TRANSPLANTATION; QUALITY OF LIFE; RIBAVIRIN;

EID: 13244281792     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2005.00563.x     Document Type: Review

References (103)

1. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26 (3 Suppl.): 62S-65S.
2. CDC. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related disease. MMWR Recomm Rep 1998; 47 (RR-19); 1-40.
3. Alter MJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-562.
4. Anonymous. EASL International Consensus Conference on Hepatitis C. J Hepatol 1999; 31: 3-8.
5. Mansell CJ, Locarnini SA. Epidemiology of hepatitis C in the East. Semin Liver Dis 1995; 15: 15-32.
6. Anonymous. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hep 1999; 6: 35-47.
7. Anonymous. Management of hepatitis C. NIH Consensus Statement. Hepatology 1997; 15 (Suppl): 1-41.
8. Bonino F, Oliveri F, Colombatto P, Calvo PL, Brunetto MR. Hepatitis C virus infection and liver disease. Acta Gastroenterol Belg 1995; 58: 60-67.
9. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1995; 21: 650-655.
10. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-832.
11. Nishioka M, Morshed SA. Viral hepatitis in Japan: update, J Gastroenterol Hepatol 1997; 12: S36-S44.
12. Di Bisceglie AM, McHutchinson J, Rice CM. New therapeutic strategies for hepatitis C. Hepatology 2002; 35: 224-231.
13. Alter HJ, Purcell RH, Holland PV, Popper H. Transmissible agent in non-A, non-B hepatitis. Lancet 1978; 1: 459-463.
14. Bradley DW, Cook EH, Maynard JE et al. Experimental infection of chimpanzees with antihemophilic (factor VIII) materials: recovery of virus-like particles associated with non-A, non-B hepatitis. J Med Virol 1979; 3: 253-269.
15. Tabor E, Purcell RH, Gerety RJ. Primate animal models and titered inocula for the study of human hepatitis A, hepatitis B, and non-A, non-B hepatitis. J Med Primatol 1983; 12: 305-318.
16. Prince AM, Brotman B. Biological and immunological aspects of hepatitis C virus infection in chimpanzees. Curr Stud Hematol Blood Transfus 1998; 62: 250-265.
17. Feitelson MA, Larkin JD. New animal models of hepatitis B and C. ILAR J 2001; 42: 127-138.
18. Wakita T, Taya C, Katsume A et al. Efficient conditional transgene expression in hepatitis C virus cDNA transgenic mice mediated by the Cre/loxP system. J Biol Chem 1998; 273: 9001-9006.
19. Conry-Cantilena C, VanRaden M, Gibble J et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996; 334: 1691-1696.
20. Vogel W. Treatment of acute hepatitis C virus infection. J Hepatol 1999; 31 (Suppl. 1): 189-192.
21. Jaeckel E, Cornberg M, Santantonio T et al. Treatment of acute hepatitis C infection with interferon-alfa 2b monotherapy prevents development of chronic HCV infection. Gastroenterology 2001; 120 (Suppl. 1): 567.
22. Cacciarelli TV, Martinez OM, Gish RG, Villanueva JC, Krams SM. Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa. Hepatology 1996; 24: 6-9.
23. Zeuzem S, Schmidt JM, Lee JH, Ruster B, Roth WK. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996; 23: 366-371.
24. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347-356.
25. Kasahara A, Hayashi N, Mochizuki K et al. Risk factors for hepatocellular carcinoma among chronic hepatitis C patients treated with interferon. Hepatology 1996; 24 (Suppl.): 397.
26. Serfaty L, Aumaitre H, Chazouilleres O et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998; 27: 1435-1440.
27. Poynard T, Leroy V, Cohard M et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778-789.
28. Chemello L, Bonetti P, Cavalletto L et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995; 22: 700-706.
29. Marcellin P, Pouteau M, Martinot-Peignoux M et al. Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology 1995; 109: 156-165.
30. Chemello L, Cavalletto L, Casarin C et al. Persistent hepatitis C viremia predicts late relapse after sustained response to Interferon-alpha in chronic hepatitis C. Ann Intern Med 1996; 124: 1058-1060.
31. Lindsay KL, Davis GL, Schiff ER et al. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatology 1996; 24: 1034-1040.
32. Patterson JL, Fernandez-Larsson R. Molecular mechanisms of action of ribavirin. Rev Infect Dis 1990; 12: 1139-1146.
33. Fang SH, Lai MY, Hwang LH et al. Ribavirin enhances interferon-gamma levels in patients with chronic hepatitis C treated with interferon-alpha. J Biomed Sci 2001; 8: 484-491.
34. DiBisceglie AM, Shindo M, Fong TL et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992; 16: 649-654.
35. Dusheiko G, Main J, Thomas H et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996; 25: 591-598.
36. Bodenheimer HC, Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997; 26: 473-477.
37. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-1492.
38. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-1432.
39. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83-87.
40. Formann E, Jessner W, Bennett L, Ferenci P. Twice weekly administration of peginterferon alfa-2b improves viral kinetics in patients with chronic hepatitis C genotype 1. J Viral Hep 2003; 10: 271-276.
41. Glue P, Fang JW, Rouzier-Panis R et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000; 68: 556-567.
42. Algranati NE, Sy S, Modi M et al. A branched methoxy 40 KDA polyethylene glycol (PEG) moiety optimizes the pharmacokinetics of peginterferon alpha-2A and may explain its enchanced efficacy in chronic hepatitis C. Hepatology 1999; 30 (Suppl.): 190.
43. Manns MP, McHutchinson J, Gordon S et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
44. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
45. Lindsay KL, Trepo C, Heintges T et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403.
46. Reddy KR, Wright TL, Pockros PJ et al. Efficacy and safety of pegylated (40-kd) interferon α-2a compared with interferon α-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33: 433-438.
47. Zeuzem S, Feinman SV, Rasenack J et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-1672.
48. Lo Iacono O, Castro A, Diago M et al. Interferon alfa-2b plus ribavirin for chronic hepatitis C patients who have not responded to interferon monotherapy. Aliment Pharmacol Ther 2000; 14: 463-469.
49. Moreno-Monteagudo JA, Castro A, De Pedro A et al. Interferon-alpha plus ribavirin for 12 months increases the sustained response rates in chronic hepatitis C relapsers. Aliment Pharmacol Ther 2002; 16: 243-249.
50. Davis GL, Esteban-Mur R, Rustgi V et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339: 1493-1499.
51. Cummings KJ, Lee SM, West ES et al. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: a meta-analysis of randomized trials. JAMA 2001; 285: 193-199.
52. Sulkowski M, Rothstein KD, Stein L et al. Peg-interferon alfa-2b plus ribavirin for treatment of patients with chronic hepatitis C who have previously failed to achieve a sustained virologic response following interferon alfa or interferon alfa-2b plus ribavirin therapy. Hepatology 2001; 34 (4 Pt 2): 419A.
53. Shiffman ML. Retreatment of interferon and interferon-ribavirin non-responders with peginterferon alpha-2a and ribavirin: initial results from the lead-phase of the HALT-C. Hepatology 2001; 34 (4 Pt 2): 243A.
54. Jacobson IM, Russo MW, Brown RS et al. Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: a trial in prior nonresponders to interferon monotherapy or combination therapy, and in combination therapy relapsers. Gastroenterology 2001; 120 (Suppl. 1): 383A.
55. Dalke DD, Donovan J, Goff J, Monsour H. PEG12000-IFN alfa 2b 0.5 meg/kg + ribavirin 800 mg/day vs. PEG12000-IFN alfa 2b 1.5 mcg/kg + ribavirin 800 mg/day for 48 weeks for treatment of patients with hepatitis C who failed or relapsed after treatment with combination therapy (Rebetron)-interim results. Hepatology 2001; 34 (4 Pt 2): 335A.
56. Heathcote EJ, Shiffman ML, Cooksley WG et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673-1680.
57. Hadziyannis SJ, Cheinquer H, Morgan T et al. Peginterferon alfa-2a (40 KD) (Pegasys) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and ribavirin dose. J Hepatol 2002; 36 (Suppl. 1): 3.
58. Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 2002; 36 (5 Pt 2): S179-S184.
59. National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002; 36 (5 Pt 2): S3-S20.
60. Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. J Acquir Immune Defic Syndr 1993; 6: 602-610.
61. Garcia-Samaniego J, Soriano V, Castilla J et al. Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. The Hepatitis/HIV Spanish Study Group. Am J Gastroenterol 1997; 92: 1130-1134.
62. Sanchez-Quijano A, Andreu J, Gavilan F et al. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis 1995; 14: 949-953.
63. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283: 74-80.
64. Zylberberg H, Benhamou Y, Lagneaux JL et al. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut 2000; 47: 694-697.
65. Landau A, Batisse D, Van Huyen JP et al. Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients. AIDS 2000; 14: 839-844.
66. Cargnel A, Casella A, Angeli E, Gubertini G, Orlando G, Duca P. Pegylated interferon alfa-2b (PEG-IFN) plus ribavirin versus PEG-IFN for treatment of HIV/HCV co-infected patients: an open, multicenter randomized trial. Gastroenterology 2002; 122 (4 Suppl. 1): A630.
67. Samuel D, Feray C. Recurrent hepatitis C after liver transplantation: clinical and therapeutical issues. J Viral Hepat 2000; 7: 87-92.
68. Manzarbeitia C, Tepermann L, Chalasani N et al. 40 KDA peginterferon alfa-2a (Pegasys) as a prophylaxis against hepatitis C infection recurrence after liver transplantation (LT): preliminary results of a randomized multicenter trial. Hepatology 2001; 34 (4 Pt 2): 406A.
69. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36 (5 Pt 2): S237-S244.
70. Koff RS. Impaired health-related quality of life in chronic hepatitis C: the how, but not the why. Hepatology 1999; 29: 277-279.
71. McHutchison JG, Ware JE, Jr, Bayliss MS et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001; 34: 140-147.
72. Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 1999; 29: 264-270.
73. Ware JE, Jr, Bayliss MS, Mannocchia M, Davis GL. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology 1999; 30: 550-555.
74. Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002; 35: 704-708.
75. Rasenack J, Zeuzem S, Feinman SV et al. Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C. Pharmacoeconomics 2003; 21: 341-349.
76. Younossi ZM, Mullen KD, Zakko W et al. Interferon alpha-2B-ribavirin vs interferon alpha-2B-amantadine combination in chronic hepatitis C: analyses of a randomized double-blind trial. Hepatology 1999; 30 (Suppl.): 372.
77. Zeuzem S, Teuber G, Naumann U et al. Randomized, double-blind, placebo-controlled trial of interferon alfa2a with and without amantadine as initial treatment for chronic hepatitis C. Hepatology 2000; 32: 835-841.
78. Caronia S, Bassendine MF, Barry R et al. Interferon plus amantadine versus interferon alone in the treatment of naive patients with chronic hepatitis C: a UK multicentre study. J Hepatol 2001; 35: 512-516.
79. Diago M, Garcia V, Valeros MD et al. Amantadine plus interferon in non responder or relapsing chronic hepatitis C patients: end of treatment response. J Hepatol 1999; 30 (Suppl. 1): 139.
80. Teuber G, Berg T, Naumann U et al. Randomized, placebo-controlled, double-blind trial with interferon-alpha with and without amantadine sulphate in primary interferon-alpha nonresponders with chronic hepatitis C. J Viral Hepat 2001; 8: 276-283.
81. Adinolfi LE, Marracino M, Tonziello A et al. Interferon induction plus ribavirin and amantadine as a novel approach for treatment of interferon nonresponder chronic hepatitis C patients. Hepatology 2000; 32: 352.
82. Cornberg M, Jaeckel E, Schueler A et al. Treatment of chronic hepatitis C in nonresponder patients with high daily induction dosing of interferon-alfa, ribavirin and amantadine/placebo. Hepatology 2000; 32: 351.
83. Younossi ZM, Mullen KD, Hodnick S et al. Triple combination of interferon A2B, ribavirin and amantadine for hepatitis C treatment failures. Hepatology 2000; 32: 444.
84. Jaeckel E, Koerbel J, Kunka A et al. Triple vs double therapy of chronic hepatitis C infection in non-responder patients with high daily induction dosing of interferon alfa. Hepatology 1999; 30 (Suppl.): 631.
85. Brillanti S, Levantesi F, Masi L, Foli M, Bolondi L. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C. Hepatology 2000; 32: 630-634.
86. Brillanti S, Miglioli M, Barbara L. Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience. J Hepatol 1995; 23 (Suppl. 2): 13-15.
87. Pardo M, Castillo I, Oliva H et al. A pilot study of recombinant interleukin-2 for treatment of chronic hepatitis C. Hepatology 1997; 26: 1318-1321.
88. Zeuzem S, Hopf U, Carreno V et al. A phase I/II study of recombinant human interIeukin-12 in patients with chronic hepatitis C. Hepatology 1999; 29: 1280-1287.
89. Nelson DR, Lauwers GY, Lau JY et al. A pilot study of recombinant human interleukin 10 (Tenovil TM) in patients with chronic hepatitis C who failed interferon-based therapy. Hepatology 1999; 30 (Suppl.): 189.
90. Rigopoulou EI, Abbott WG, Williams R, Lau JYN, Naoumov NV. Blocking of IL-10 receptor - a novel approach to stimulate virus-specific T cell reactivity in chronic hepatitis C virus (HCV) infection. Hepatology 2000; 32 (4 Pt 2): 304A.
91. Caselmann WH, Eisenhardt S, Alt M. Synthetic antisense oligodeoxynucleotides as potential drugs against hepatitis C. Intervirology 1997; 40: 394-399.
92. Welch PJ, Yei S, Barber JR. Ribozyme gene therapy for hepatitis C virus infection. Clin Diagn Viro 1998; 10: 163-171.
93. Hinrichsen H, Benhamou Y, Reiser M et al. First report on the antiviral efficacy of BILN 2061, a novel oral HCV serine protease inhibitor, in patients with chronic hepatitis C genotype 1. Hepatology 2002; 36 (4 Pt 2): 379A.
94. McEvoy GK, Litvak K, Welsh OH (eds). American Hospital Formulary Service Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 2002; 3765 pp.
95. Andreone P, Cursaro C, Gramenzi A et al. In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C. J Viral Hepat 2001; 8: 194-201.
96. Kullavanuaya P, Treeprasertsuk S, Thong-Ngam D, Chaermthai K, Gonlachanvit S, Suwanagool P. The combined treatment of interferon alpha-2a and thymosin alpha 1 for chronic hepatitis C: the 48 weeks end of treatment results. J Med Assoc Thai 2001; 84 (Suppl. 1): S462-S468.
97. Negro F, Male PJ, Perrin L, Giostra E, Hadengue A. Treatment of chronic hepatitis C with alpha-interferon plus ofloxacin in patients not responding to alpha-interferon alone. J Hepatol 1998; 29: 369-374.
98. Tabone M, Ercole E, Zaffino C, SallioBruno F, Pera A, Bonino F. Amantadine hydrochloride decreases serum ALT activity without effects on serum HCV-RNA in chronic hepatitis C patients. Ital J Gastroenterol Hepatol 1998; 30: 611-613.
99. Tabon M, Laudi C, Delmastro B et al. Interferon and amantadine in combination as initial treatment for chronic hepatitis C patients. J Hepatol 2001; 35: 517-521.
100. De Rosa SC, Zaretsky MD, Dubs JG et al. N-acetylcysteine replenishes glutathione in HIV infection. Eur J Clin Invest 2000; 30: 915-929.
101. Grant PR, Black A, Garcia N, Prieto J, Garson JA. Combination therapy with interferon-alpha plus N-acetyl cysteine for chronic hepatitis C: a placebo controlled double-blind multicentre study. J Med Virol 2000; 61: 439-442.
102. Puoti C, Magrini A, Filippi T, Annovazzi G, Pannullo A. Effects of ursodeoxycholic acid on serum liver enzymes in patients with hepatitis C virus-related chronic liver disease. Eur J Gastroenterol Hepatol 1995; 7: 151-154.
103. Poupon RE, Bonnand AM, Queneau PE et al. Randomized trial of interferon-alpha plus ursodeoxycholic acid versus interferon plus placebo in patients with chronic hepatitis C resistant to interferon. Scand J Gastroenterol 2000; 35: 642-649.